Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Anti-Fibrotic Agent PLN-74809

Next Previous
Search
Trial Profile

A Phase 1a, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Anti-Fibrotic Agent PLN-74809

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexotegrast (Primary)
  • Indications Idiopathic pulmonary fibrosis; Primary sclerosing cholangitis
  • Focus Adverse reactions; First in man
  • Sponsors Pliant Therapeutics

Most Recent Events

  • 18 May 2022 According to a Pliant Therapeutics media release, data from this study were presented at the 2022 American Thoracic Society (ATS) International Conference.
  • 24 Sep 2020 According to a Pliant Therapeutics media release, data from this study was presented at the American Thoracic Society 2020 Virtual Sessions.
  • 24 Sep 2020 Results published in the Pliant Therapeutics Media Release

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top